Welcome to our dedicated page for SOAN news (Ticker: SOAN), a resource for investors and traders seeking the latest updates and insights on SOAN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SOAN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SOAN's position in the market.
GlobeStar Therapeutics Corporation (formerly AngioSoma, OTC PINK:SOAN) has received FINRA approval for its name change effective immediately as of July 6, 2021. The company shifts focus towards medical research and treatments, particularly for neurodegenerative diseases like Multiple Sclerosis. A new CUSIP number (37960P104) will be issued, and a new website is set to launch soon, featuring an expanded health library. CEO James C. Katzaroff expressed enthusiasm for the name change, emphasizing the company's commitment to growth in healthcare.
AngioSoma, Inc. (OTC PINK:SOAN) has appointed Kaushik Srinivasan, former CEO of Radiant Health, to its Advisory Board. His extensive experience in the healthcare sector, particularly in neurological trauma and medical management, will enhance AngioSoma's capabilities. The company, focused on innovative healthcare solutions, aims to assist patients with chronic diseases, including Multiple Sclerosis. President James C. Katzaroff expressed excitement about Srinivasan's addition, which he believes will help the company advance its mission of improving patient outcomes.
AngioSoma, Inc. (OTC PINK:SOAN) has appointed Dr. Michael Lewis, MD, to its Medical Advisory Board, enhancing its team with his extensive experience in patient care and research.
Dr. Lewis specializes in nutritional interventions for brain health and has a distinguished military background, including roles in various health organizations.
The company emphasizes the importance of medical collaboration to advance treatments for diseases like Multiple Sclerosis, aligning with its mission to support patient wellness.
AngioSoma, Inc. (OTC PINK:SOAN) has appointed Sichenzia Ross Ference, LLP as its outside securities counsel, leveraging their expertise in healthcare. AngioSoma is focused on innovative treatments for Multiple Sclerosis and aims to gain regulatory clearance for a new MS treatment based on licensing agreements. The law firm is recognized for its competence in securities law and has been awarded the U.S. News & World Report's 'Best Law Firm' designation for three consecutive years. AngioSoma emphasizes a commitment to improving healthcare solutions for chronic diseases.
AngioSoma, Inc. (OTC PINK: SOAN) has appointed Robert Chicoski as its new Chief Financial Officer and Treasurer. Chicoski brings extensive financial expertise, including corporate finance and audit experience. The company, headquartered in Richland, Washington, is focused on innovating medical treatments, particularly in the field of wellness and diseases like Multiple Sclerosis. CEO James C. Katzaroff expressed confidence in Chicoski's ability to enhance the company’s financial operations. AngioSoma is committed to improving health through effective healthcare solutions.
AngioSoma, Inc. (OTC PINK:SOAN) has appointed Darryl Morris as a Strategic Economic Advisor, bringing over three decades of experience in economic and market intelligence. Morris has worked with notable companies like Abbott Laboratories and offers expertise in market strategy and financial support. The company, based in Richland, Washington, focuses on medical research and treatment solutions, particularly for diseases such as Multiple Sclerosis. Morris aims to enhance AngioSoma's capabilities to provide innovative healthcare solutions.
AngioSoma, Inc. (OTC PINK:SOAN) has appointed Dr. Leonard Wisneski, MD, FACP as Chair of the Medical Advisory Board. His extensive background in patient care and integrative health, coupled with leadership roles at major healthcare organizations, is anticipated to enhance AngioSoma's clinical trials and medical outreach. The company aims to address challenges in diseases like Multiple Sclerosis and is focused on developing innovative health solutions. This strategic move may contribute positively to their growth trajectory and medical initiatives.
AngioSoma, Inc. (OTC PINK:SOAN) has appointed Steven F. Penderghast to its Board of Directors, bringing over 30 years of experience in medical sciences and leadership from major healthcare organizations like Baxter Healthcare and CR Bard Inc. His expertise in clinical and product development, particularly in medical devices, is expected to enhance AngioSoma's mission of developing treatments for wellness and diseases such as Multiple Sclerosis. This leadership change aims to strengthen the company’s growth and innovation in the medical sector.
AngioSoma, Inc. (OTC PINK:SOAN) has appointed David Croom as Executive Vice President, enhancing its executive team with his extensive experience in finance, sales, and operations. Croom's role will focus on operational efficiency and driving sales, supporting the company's mission to advance medical research and treatments, particularly for autoimmune diseases like Multiple Sclerosis. CEO James C. Katzaroff emphasized the importance of Croom's expertise in achieving the company’s growth objectives. AngioSoma is actively working on innovative therapies and engaging with contract research organizations for its drug application submissions.
AngioSoma, Inc. (OTC PINK:SOAN) has appointed Brooke Greenwald as its new Chief Marketing Officer. With over three decades of experience in healthcare marketing and public relations, Greenwald is expected to enhance AngioSoma's efforts in medical research and treatment development, particularly for diseases like Multiple Sclerosis. This strategic hire aims to bolster the company's branding and outreach initiatives in the healthcare sector. AngioSoma is actively pursuing innovative solutions for rare disorders, highlighting its commitment to improving human health.
